Lipoprotein(a) Evaluation and Management
Measure Lp(a) once in every adult's lifetime as part of initial lipid screening, and if elevated ≥50 mg/dL (≥100 nmol/L), aggressively optimize all modifiable cardiovascular risk factors with intensive LDL-C lowering as the primary therapeutic target. 1
Screening Recommendations
The 2021 Canadian Cardiovascular Society guidelines provide the most definitive screening recommendation: measure Lp(a) once in a lifetime as part of initial lipid screening 1. This is a strong recommendation based on high-quality evidence. No repeat measurements are needed since Lp(a) levels are genetically determined, stable throughout life, and not influenced by age, sex, fasting state, inflammation, or lifestyle factors 1.
The threshold for clinical concern is Lp(a) ≥50 mg/dL (≥100 nmol/L), which affects approximately 20% of individuals of European and South Asian descent, 40% of African Americans, and fewer than 10% of East Asians 1.
Risk Stratification
Elevated Lp(a) confers cardiovascular risk in a dose-dependent manner:
- 10-49 mg/dL: 1.28-fold increased risk of major adverse cardiovascular events (MACE)
- 50-99 mg/dL: 1.44-fold increased risk
- ≥100 mg/dL: 2.14-fold increased risk 1
The 2019 AHA/ACC guidelines classify Lp(a) ≥50 mg/dL (≥125 nmol/L) as a risk-enhancing factor 2, particularly important in patients with family history of premature ASCVD or personal history of ASCVD not explained by major risk factors.
Management Strategy: Primary Prevention
For patients with elevated Lp(a) in primary prevention settings 1:
1. Intensive Risk Factor Modification
- Earlier and more aggressive health behavior counseling
- Comprehensive ASCVD risk assessment including consideration of coronary artery calcium (CAC) scoring in select individuals
- Aggressive management of all modifiable risk factors (hypertension, smoking cessation, diabetes control, obesity)
2. LDL-C Lowering as Primary Target
Earlier introduction of statin therapy, particularly in:
- Intermediate-risk individuals with Lp(a) ≥50 mg/dL
- Low-risk individuals with moderate LDL-C elevations (3.5-5 mmol/L or 135-193 mg/dL) and elevated Lp(a)
The rationale: While Lp(a) itself is not currently a treatment target, aggressive LDL-C lowering mitigates the residual cardiovascular risk associated with elevated Lp(a) 1.
Management Strategy: Secondary Prevention
In patients with established ASCVD and elevated Lp(a), intensify LDL-lowering therapy including PCSK9 inhibitors 1.
Therapeutic Options:
PCSK9 Inhibitors (alirocumab, evolocumab):
- Reduce Lp(a) by approximately 20-30% (secondary to LDL-C lowering effect)
- Post-hoc analysis from ODYSSEY OUTCOMES showed alirocumab-associated Lp(a) reductions reduced MACE in patients with recent ACS independent of LDL-C lowering 1
- Consider particularly in high-risk patients with Lp(a) ≥100 mg/dL and progressive ASCVD despite optimal statin therapy
Lipoprotein Apheresis:
- The only therapy achieving substantial Lp(a) reduction (60-75%)
- Reserved for extreme elevations with progressive ASCVD despite maximal medical therapy
- Limited by invasiveness, cost, and availability 1
Important Caveats:
Therapies that DO NOT lower Lp(a) 1:
- Statins (may modestly raise levels)
- Ezetimibe
- Lifestyle modifications
Niacin: While it lowers Lp(a), it has not been shown to reduce cardiovascular or all-cause mortality and should not be used solely for Lp(a) reduction 1.
Family Screening
Individuals with extreme Lp(a) elevations have event rates similar to familial hypercholesterolemia, justifying cascade screening in high-risk families 1. This is particularly important in families with premature ASCVD where Lp(a) may be the underlying genetic cause.
Clinical Pitfalls to Avoid
Do not repeat Lp(a) measurements for risk assessment—levels are stable and genetically determined 1
Do not use Lp(a) as a treatment target—there is no RCT evidence that specifically lowering Lp(a) reduces cardiovascular outcomes (though trials with antisense oligonucleotides and siRNA are ongoing) 1
Recognize that "LDL-C" includes Lp(a)-cholesterol—standard LDL-C assays cannot separate the cholesterol portion of Lp(a) from LDL-C, meaning reported "LDL-C" is actually LDL-C + Lp(a)-C 3
Consider lipid specialist consultation when uncertain about implications of elevated Lp(a), particularly in patients with extreme elevations (≥100 mg/dL) or progressive ASCVD 1
Future Therapies
Antisense oligonucleotides and small interfering RNAs achieving 80-95% Lp(a) reductions are in phase 3 clinical trials 1. Until outcome data are available, management remains focused on aggressive optimization of modifiable risk factors and intensive LDL-C lowering.